1. Infection

Infection

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-131350
    LXE408 1799330-15-6 99.08%
    LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC50 of 0.04 μM for L. donovani proteasome and an EC50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain barrier. LXE408 has the potential for visceral leishmaniasis (VL) research.
    LXE408
  • HY-148797
    Rolusafine 2089153-78-4 98.78%
    Rolusafine is an antifungal agent.
    Rolusafine
  • HY-B0277A
    Vidarabine phosphate 29984-33-6 98.74%
    Vidarabine phosphate (Ara-AMP), an antiviral agent, inhibits chronic HBV infection. Vidarabine phosphate also against herpes simplex and varicella zoster viruses.
    Vidarabine phosphate
  • HY-P99346
    Regdanvimab 2444308-95-4
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
    Regdanvimab
  • HY-P99435
    Amubarvimab 2509447-07-6
    Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
    Amubarvimab
  • HY-P99564
    Teropavimab 2417213-72-8 99.00%
    Teropavimab (3BNC117-LS) is an antibody. Teropavimab can be used for the research of HIV infection.
    Teropavimab
  • HY-U00160
    SP187 615253-61-7 ≥98.0%
    SP187 is a host-targeted iminosugar with activity against filovirus infections in vitro and in vivo. SP187 is active against influenza and dengue in vivo.
    SP187
  • HY-106574A
    Ceftobiprole medocaril sodium 252188-71-9
    Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens.
    Ceftobiprole medocaril sodium
  • HY-123475A
    Sisunatovir hydrochloride 1903763-83-6 98.61%
    Sisunatovir (RV521) hydrochloride is a potent and orally active respiratory syncytial virus (RSV) inhibitor with IC50 values of 1.4, 1.0 nM for RSV A, RSV B, respectively. Sisunatovir hydrochloride inhibits RSV infection and reduces virus titers in the lungs of mice.
    Sisunatovir hydrochloride
  • HY-19964
    Potassium clavulanate cellulose ≥98.0%
    Potassium clavulanate cellulose (Potassium clavulanate:cellulose (1:1)) is a mixture of potassium clavulanate and cellulose, is a bacterial β-lactamase inhibitor. Clavulanate potassium is a form of Clavulanic acid. Clavulanate potassium fights bacteria that resistant to penicillins and other antibiotics. Potassium clavulanate with the combination of amoxicillin can be used for the research of different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.
    Potassium clavulanate cellulose
  • HY-B0502S
    Enrofloxacin-d5 1173021-92-5 99.82%
    Enrofloxacin-d5 is the deuterium labeled Enrofloxacin. Enrofloxacin (BAY Vp 2674) is an effective antibiotic with an MIC90 of 0.312 μg/mL for Mycoplasma bovis.
    Enrofloxacin-d5
  • HY-11098
    JNJ 2408068 317846-22-3
    JNJ 2408068 is a potent RSV (respiratory syncytial virus) inhibitor. JNJ 2408068 significantly inhibits replication of RSV A and B subtypes in the lungs of cotton rats without any evidence of toxicity. The minimum protective dose of JNJ 2408068 appears to be approximately 0.39 mg/kg.
    JNJ 2408068
  • HY-12904
    TCA1 864941-32-2 98.29%
    TCA1 is a small molecule with activity against agent-susceptible and -resistant Mycobacterium tuberculosis (Mtb). TCA1 inhibits enzymes involved in cell wall and molybdenum cofactor biosynthesis, such as DprE1 and MoeW.
    TCA1
  • HY-12994
    VP-14637 235106-62-4 ≥99.0%
    MDT-637 (VP 14637) is a novel respiratory syncytial virus (RSV) fusion inhibitor with an IC50 of 1.42 ng/mL.
    VP-14637
  • HY-13833
    Endochin 354155-51-4 ≥98.0%
    Endochin is an antimalarial agent. Endochin inhibits T.gondii with an IC50 of 0.003 nM. Endochin is also active against experimental toxoplasmosis.
    Endochin
  • HY-15297
    Vesnarinone 81840-15-5 98.58%
    Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research.
    Vesnarinone
  • HY-15353
    Emivirine 149950-60-7 99.73%
    Emivirine (MKC-442) is a non-nucleoside reverse transcriptase inhibitors (NNRTIs) with Ki values of 0.20 and 0.01 μM for dTTP- and dGTP-dependent DNA or RNA polymerase activity, respectively. Emivirine displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity.
    Emivirine
  • HY-15355
    Loviride 147362-57-0 99.59%
    Loviride (R 89439) is a non-nucleoside reverse transcriptase inhibitor (NNRTI), with an IC50 of 0.3 µM for reverse transcriptase from HIV-1. Loviride (R 89439) inhibits HIV-1, HIV-2 and SIV replication in MT-4 cells.
    Loviride
  • HY-16719
    Dapaconazole 1269726-67-1 99.76%
    Dapaconazole, as an antifungal agent, inhibits sterol 14α-demethylase cytochrome P450 activity with an IC50 of 1.4 μM.
    Dapaconazole
  • HY-16745
    Lascufloxacin 848416-07-9 98.04%
    Lascufloxacin (KRP-AM1977X) is a potent and orally active fluoroquinolone antibacterial agent. Lascufloxacin potently inhibits infections caused by various pathogens, including quinolone-resistant strains. Lascufloxacin has the potential for various infectious diseases treatment, including lower respiratory tract infections.
    Lascufloxacin
Cat. No. Product Name / Synonyms Application Reactivity